A Multicentre, Open-label Trial Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Acronyms guardian ™9
- Sponsors Novo Nordisk
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 29 May 2017 Planned End Date changed from 7 Jul 2017 to 6 Jul 2017.
- 29 May 2017 Planned primary completion date changed from 5 May 2017 to 31 May 2017.